Success Metrics

Completion Rate
0%(0/1)
Active Trials
5(83%)
Terminated
1(17%)

Phase Distribution

Ph not_applicable
1
17%
Ph phase_2
3
50%
Ph phase_3
2
33%

Phase Distribution

0

Early Stage

3

Mid Stage

2

Late Stage

Phase Distribution6 total trials
Phase 2Efficacy & side effects
3(50.0%)
Phase 3Large-scale testing
2(33.3%)
N/ANon-phased studies
1(16.7%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 1 finished

Non-Completion Rate

100.0%

1 ended early

Currently Active

5

trials recruiting

Total Trials

6

all time

Status Distribution
Active(5)
Terminated(1)

Detailed Status

Recruiting5
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
5
Success Rate
0.0%
Most Advanced
Phase 3

Trials by Phase

Phase 23 (50.0%)
Phase 32 (33.3%)
N/A1 (16.7%)

Trials by Status

recruiting583%
terminated117%

Recent Activity

5 active trials
Showing 5 of 6
recruitingphase_2

A Multicohort Study of Toripalimab in Combination With Investigator-Selected Chemotherapy for Advanced HER2-Negative Breast Cancer

NCT07540533
recruitingphase_3

Precise Treatment for BLIS Subtype of TNBC in the First-line Treatment of Locally Advanced or Metastatic Breast Cancer

NCT05806060
recruitingphase_2

A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer

NCT06099769
recruitingnot_applicable

Capecitabine and Cyclophosphamide (XC) as Maintenance Therapy for Advanced Breast Cancer

NCT05876065
recruitingphase_2

SNF Platform Study of HR+/ HER2-advanced Breast Cancer

NCT05594095
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT07540533Phase 2

A Multicohort Study of Toripalimab in Combination With Investigator-Selected Chemotherapy for Advanced HER2-Negative Breast Cancer

Recruiting
NCT05806060Phase 3

Precise Treatment for BLIS Subtype of TNBC in the First-line Treatment of Locally Advanced or Metastatic Breast Cancer

Recruiting
NCT06099769Phase 2

A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer

Recruiting
NCT05876065Not Applicable

Capecitabine and Cyclophosphamide (XC) as Maintenance Therapy for Advanced Breast Cancer

Recruiting
NCT05594095Phase 2

SNF Platform Study of HR+/ HER2-advanced Breast Cancer

Recruiting
NCT03055312Phase 3

Bicalutamide in Treatment of Androgen Receptor (AR) Positive Metastatic Triple Negative Breast Cancer

Terminated

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6